AVACEN Medical's new concept for chro...
Home  »  Community News  »  AVACEN Medical's new...
AVACEN Medical’s new concept for chronic pain treatment receives US patent
Pharma News

San Diego
Saturday, November 28, 2015, 14:00 Hrs  [IST]

AVACEN Medical, a company dedicated to the innovation and design of safe,  easy to use, noninvasive drug free alternatives to treat pain associated with diseases, announced that the United States Patent and Trademark Office (USPTO) has granted US patent No. 9,192,509 entitled: “Methods and Apparatus for Therapeutic Application of Thermal Energy Including Blood Viscosity Adjustment”. This patent shields the company’s AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the company as the AVACEN Treatment Method.

The AVACEN 100, a unique FDA-Cleared muscular relaxation device, is the world’s first noninvasive device that is designed to allow patients to treat their entire body from a single convenient body location (the palm). Integrating the health benefits of a dry heat sauna and hyperbaric oxygen treatment, this may be the cost-effective solution chronic pain suffers have been searching for.

According to AVACEN Medical CEO and inventor, Thomas Muehlbauer, “The patented AVACEN Treatment Method is an entirely new concept in chronic pain treatment through muscular relaxation by bathing the skeletal muscles with warm oxygenated and nutritious blood.”

With over 3,000 programmed microprocessor instructions, the company’s AVACEN 100 device meticulously manages the noninvasive and safe continued infusion of heat into the circulatory system using negative pressure and a conductive heat source (not LED or Infrared). It accomplishes this by taking advantage of a unique arrangement of blood vessels called the arteriovenous anastomosis (AVA’s) in the palm of the hand. The AVA’s normally act as the body’s radiator to dump excess heat to avert overheating. The AVACEN 100 manipulates the same AVA’s so they can be used as a portal to infuse heat into the circulatory system. When dilated and distended by the AVACEN 100, blood flow through an AVA can be 1,000 times more than the smaller capillary.

Muehlbauer added, “The key is the continued infusion of heat into the circulatory system when the body is at normothermia, approximately 98.6°F. The heat acts as a catalyst to reduce the viscosity of the blood. The result is that the body must dissipate the unwanted heat by pumping the warmed and thinner blood through the skeletal muscles to reach the heat exchange capillary network where it can be cooled by the ambient air. It should be noted that the level of heat is precisely controlled so that it cannot induce heatstroke. Actually, the level of infused heat normally doesn’t even engage the sweat glands.”

“Overall, our process increases microcirculation. The main functions of microcirculation are to deliver oxygen and nutrients and remove carbon dioxide (CO2) from the deep tissues. Microcirculation also serves to regulate tissue blood flow.  This affects blood pressure and responses to inflammation, including edema (swelling), and chronic pain associated with numerous medical afflictions such as CRPS, lyme disease, fibromyalgia, rheumatoid arthritis, Raynaud’s disease and carpal tunnel syndrome.”

“Understanding the use of the palm as a single point of treatment, is really quite simple.  Basically, the heart pumps the warmed and thinner blood originating in the palm to all organ and muscle tissues. In other words, wherever blood flows, enhanced oxygen delivery and nutrition occurs. The overall benefits to the human aging process could be enormous!”

“For our process to be effective the body must be at normothermia. Low body temperature is not healthy, as most of the important bodily enzymes function best at or near normothermia. Therefore in the case of low core body temperature, our initial transfer of heat into the circulatory system elevates the body to normothermia.”


Courtesy – Pharmabiz

Leave a reply

You must be logged in to post a comment.